Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:biosimilar |
| gptkbp:activeIngredient |
gptkb:adalimumab
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L04AB04
|
| gptkbp:brand |
gptkb:Cyltezo
|
| gptkbp:indication |
gptkb:Crohn's_disease
gptkb:psoriatic_arthritis ulcerative colitis rheumatoid arthritis ankylosing spondylitis plaque psoriasis |
| gptkbp:isBiosimilarTo |
gptkb:Humira
|
| gptkbp:manufacturer |
gptkb:Boehringer_Ingelheim
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:bfsParent |
gptkb:Cyltezo
|
| gptkbp:bfsLayer |
8
|
| http://www.w3.org/2000/01/rdf-schema#label |
adalimumab-adbm
|